Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00413764
Other study ID # P06089
Secondary ID C-1774
Status Completed
Phase Phase 3
First received
Last updated
Start date March 23, 2004
Est. completion date November 15, 2005

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tibolone has been registered for treatment of menopausal symptoms. It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction. This is important because there is currently no approved treatment of libido problems in postmenopausal women. Therefore, the primary aim of this study was to compare the effects of tibolone with an estrogen/progestogen skin patch in postmenopausal women diagnosed sexual dysfunction.


Recruitment information / eligibility

Status Completed
Enrollment 358
Est. completion date November 15, 2005
Est. primary completion date November 15, 2005
Accepts healthy volunteers No
Gender Female
Age group 48 Years to 68 Years
Eligibility Inclusion Criteria: - Physically and mentally healthy postmenopausal women, >=48 and <=68 years of age, with an intact uterus. - Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15). - An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend? - All subjects were to have an established sexual relationship of at least 6 months duration prior to screening. - Women were to be sexually active. - Normal mammography within 6 months prior to randomization. - Body mass index >18 and <=32 kg/m2. - Voluntary written informed consent Exclusion Criteria: - Any unexplained abnormal uterine bleeding - Double layer endometrial thickness >4 mm - Tibolone or transdermal E2/NETA use within 3 months prior to screening - Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening - Use of intra-uterine progestogen - Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity - Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening - Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed) - Use of anti -androgens within the preceding 5 years prior to screening. - Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction - Women who had early onset sexual dysfunction (>15 years prior to menopause) - Women suffering from androgenic alopecia, acne or hirsutism - Women suffering from illnesses influencing sexuality - Women using medication influencing sexuality - Moderate to severe depression - Current or prior use of antidepressant within 8 weeks prior to screening - Major gynecological surgery in the preceding 3 months - Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed) - History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years - Diseases for which exogenous hormonal steroids were contraindicated. - History or presence of any malignancy, except successfully treated non-melanoma skin cancers - History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders - History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches - Uncontrolled hypertension - Women with abnormal cervical smear results - History or presence of breast cancer, suspicious breast lump or mammographic abnormality - Known hypersensitivity to any of the ingredients of the trial medication. - Non-compliance with the screening diary - Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts - Drugs known to interfere with the pharmacokinetics of the steroids - Use of investigational drugs within the past 60 days - Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
tibolone
tibolone (2.5 mg) over 24 weeks
estradiol-norethisterone
transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

References & Publications (1)

Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, Norman RJ, Mulder RJ, Davis SR; LISA study investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the effect of tibolone (2.5 mg) to transdermal E2/NETA (50/140 mcg) on the vaginal bleeding and spotting rate in healthy postmenopausal women with sexual dysfunction. Week 13-24 of the in treatment period
Primary Compare the effect of tibolone to E2/NETA on sexual functioning in healthy postmenopausal women with sexual dysfunction. Week 8-12 and Week 20-24 of the in-treatment period.
Secondary Compare the effects of tibolone to E2/NETA on the frequency of satisfactory sexual events, the frequency of sexual fantasies and subjective arousal, scores on the FSFI, FSDS, WHQ and endocrine parameters Week 8-12 and Week 20-24 of the in-treatment period
See also
  Status Clinical Trial Phase
Recruiting NCT05039775 - Clitoral Therapy Device in Alleviating Sexual Dysfunction After Genital Mutilation. N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A
Not yet recruiting NCT05918770 - Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients N/A
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Completed NCT02837796 - Effects of Trans-Obturator Tape outside-in Versus Inside-out Procedure for Stres Urinary Incontinence N/A
Completed NCT01660152 - Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery N/A
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Active, not recruiting NCT00981305 - Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors Phase 3
Completed NCT04964895 - Sexual Quality of Patients After Bladder Cancer Cystectomy N/A
Enrolling by invitation NCT05832268 - Pelvic Floor Function After Obstetric Injury to the Anal Sphincter
Completed NCT04066218 - Sexual Function Screening in Childhood Cancer Survivors
Not yet recruiting NCT05530681 - Correlation Pelvic Floor Function and Ultrasound Findings One Year After Childbirth N/A
Recruiting NCT05826691 - Benign Prostate Surgery and QOL and Sexual Function
Completed NCT04560283 - HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period Phase 4
Completed NCT03232801 - A Mindfulness-based Intervention for Older Women With Low Sexual Desire N/A
Suspended NCT04544735 - Improving Women's Function After Pelvic Radiation N/A
Completed NCT05732844 - Efficacy of the Use of Vaginal Balls for the Improvement of Urinary Incontinence and Sexual Function in Women. N/A
Recruiting NCT05097469 - Carbon Dioxide Acupulse Laser Treatment Versus Sham Treatment and Sexual Dysfunction. N/A
Withdrawn NCT01635543 - Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas N/A